The burden of caregiving is heavier for people who are anxious and reasonably knowledgeable about amyotrophic lateral sclerosis (ALS), a study of patients and their caregivers in China suggests. The study, “Caregiver burden and associated factors among primary caregivers of patients with ALS in home care:…
A molecule that blocks the regulatory RNA protein HuR, called SRI-42127, strongly reduces brain inflammation driven by activated glial cells, key players in neurodegenerative diseases like amyotrophic lateral sclerosis, a preclinical study reported. This inhibitor may be of promise in treating ALS and other diseases driven by inflammation in the brain. “Our…
Age, socioeconomic status, and co-existing conditions are among the factors that can lead to a need for assisted ventilation in people with amyotrophic lateral sclerosis (ALS), research from Korea reports. The study, “Factors associated with assisted ventilation use in amyotrophic lateral sclerosis: a nationwide population-based study in Korea,”…
An imaging agent developed by Ashvattha Therapeutics can accurately detect brain inflammation caused by microglia, immune cells that play a key role in neurological diseases such as amyotrophic lateral sclerosis (ALS), a mouse study reported. The company is planning to initiate a Phase 1/2 clinical trial in ALS…
Cytokinetics is accepting applications from advocacy groups working in cardiovascular and neuromuscular diseases, including amyotrophic lateral sclerosis (ALS), for grants worth $20,000 each that will help them expand their communications and community engagement. In total, five Cytokinetics Communications Fellowship Grants will be awarded winning organizations. The deadline for applications…
PathMaker Neurosystems was awarded $371,000 from the National Institutes of Health (NIH) to advance its neuromodulation technology as a potential new, non-invasive treatment for amyotrophic lateral sclerosis (ALS). The Small Business Technology Transfer grant, from the NIH’s National Institute of Neurological Disorders and Stroke, will enable PathMaker to…
Health Canada has agreed to review Amylyx Pharmaceuticals‘ application seeking approval of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). “We are pleased that our submission has been accepted for review by Health Canada, and we are committed to serving those affected by ALS in the…
Get regular updates to your inbox.